Lumakras, manufactured by Amgen Inc. and marketed under the brand name Blincyto, represents a remarkable advancement in the field of oncology, particularly for patients grappling with Non-Small Cell Lung Cancer (NSCLC). Powered by the active ingredient Sotorasib, Lumakras embodies a commitment to innovation and scientific progress, redefining the landscape of NSCLC treatment with its precision-focused approach and targeted efficacy.
Manufacturer and Product Details:
Brand Name: Lumakras
Generic Name: Sotorasib
Available Strengths: 120 mg and 320 mg (240 tablets per box size)
Manufacturer: Amgen Inc.
List of Excipients:
The excipients contained in Lumakras include:
Tablet Core: Lactose monohydrate, Microcrystalline cellulose, Croscarmellose sodium, Magnesium stearate
Film-Coating: Polyvinyl alcohol, Titanium dioxide (E171), Macrogol 3350
Key Features:
Precision Treatment: Lumakras sets a new standard in precision treatment, demonstrating unparalleled accuracy and efficacy in addressing the intricate complexities of Non-Small Cell Lung Cancer.
Cutting-edge Advancements: Developed through rigorous research and scientific breakthroughs, Lumakras represents the forefront of medical science, offering advanced solutions for NSCLC patients in need.
Tailored Formulation: Lumakras is meticulously formulated to embody the pinnacle of medical sophistication, underlining a steadfast commitment to patient well-being and therapeutic excellence.
Personalized Healing: Lumakras exemplifies the potential of personalized medicine, delivering tailored treatment regimens that acknowledge the individuality of each patient, and providing targeted and effective therapy.
Holistic Support: Complementing its efficacy, Lumakras offers comprehensive patient support resources, ensuring that patients receive guidance and information throughout their treatment journey.
Special Storage Precautions:
It is essential to store Lumakras at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F), to maintain its optimal efficacy and shelf life.
Prescription:
Lumakras, also known as Sotorasib, is a prescription medication indicated for the treatment of Non-Small Cell Lung Cancer (NSCLC). Consulting an oncologist or a qualified healthcare professional for personalized guidance and supervision throughout the treatment course is imperative.
Side Effects:
While Lumakras effectively manages NSCLC, patients should be aware of potential side effects, including nausea and vomiting, fatigue and weakness, diarrhea or constipation, loss of appetite, skin rashes or allergic reactions, and respiratory issues such as coughing or difficulty breathing. Promptly reporting any unusual symptoms or severe side effects to the healthcare provider is crucial for appropriate evaluation and management.
Conclusion:
Lumakras stands as a testament to the relentless pursuit of innovation and excellence in combating Non-Small Cell Lung Cancer, serving as a beacon of hope for patients and their loved ones. With its groundbreaking advancements and a patient-centric approach, Lumakras signifies a promising advancement in personalized and effective NSCLC treatment, illuminating the path to healing and a brighter tomorrow.